Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.
What is the ticker symbol for Celcuity Inc? What does CELC stand for in stocks?
CELC is the stock ticker symbol of Celcuity Inc. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of Celcuity Inc (CELC)?
As of Fri Dec 20 2024, market cap of Celcuity Inc is 462.63 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of CELC stock?
You can check CELC's fair value in chart for subscribers.
Is Celcuity Inc a good stock to buy?
The fair value guage provides a quick view whether CELC is over valued or under valued. Whether Celcuity Inc is cheap or expensive depends on the assumptions which impact Celcuity Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CELC.